Dr. Amir A. Rasheed, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 535
Licensed in Texas since 2009, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license N3264 (first issued 2009; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Houston Methodist Baytown Hospital Baytown, TX
- HCA Houston Healthcare Southeast Pasadena, TX
- East Houston Medical Center Houston, TX
Medical groups
- Houston Medical Consultants PA (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 535
- Services billed
- 71,166
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Injection, iron sucrose, 1 mg | 44,600 | 69 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 3,440 | 17 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 2,193 | 271 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 2,000 | 23 |
| Injection, granisetron hydrochloride, 100 mcg | 1,961 | 15 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,016 | 264 |
| Injection, dexamethasone sodium phosphate, 1 mg | 850 | 14 |
| Established patient office or other outpatient visit, 20-29 minutes | 796 | 259 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 729 | 113 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 646 | 96 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Baytown, TX | 415 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Baytown, TX | 263 |
| Procrit (epoetin alfa) | 230 |
| Anastrozole Other prescribers in Baytown, TX | 139 |
| Hydroxyurea Other prescribers in Baytown, TX | 111 |
| Keytruda (pembrolizumab) | 90 |
| Warfarin Sodium Other prescribers in Baytown, TX | 82 |
| Bortezomib | 67 |
| Jakafi (ruxolitinib phosphate) | 63 |
| Dexamethasone Other prescribers in Baytown, TX | 61 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 37 companies reported 108 payments worth $2,496 in total to this clinician.
| Pfizer Inc. | $276 |
|---|---|
| GlaxoSmithKline, LLC. | $205 |
| AstraZeneca Pharmaceuticals LP | $177 |
| Incyte Corporation | $176 |
| Merck Sharp & Dohme LLC | $155 |
| Astellas Pharma US Inc | $138 |
| Sobi, Inc | $126 |
| Rigel Pharmaceuticals, Inc. | $124 |
| Food and Beverage | $2,325 |
|---|---|
| Education | $170 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sobi, Inc Apr 28, 2025 | Education in-kind | $77.99 |
| Astellas Pharma US Inc Jul 24, 2025 | Education in-kind | $74.99 |
| Pfizer Inc. Apr 14, 2025 | Education ELREXFIO · ONCOLOGY · in-kind | $17.16 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $125,000 in research payments for these studies, mostly to the institutions running them.
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Eli Lilly and Company · Recruiting · NCT07218380 - A phase 3, randomized, double-blind, placebo-controlled study of LY4064809 combined with a CDK4/6 inhibitor and endocrine therapy in adults with hr+, HER2- advanced breast cancer with a PIK3CA mutation who received no…
Eli Lilly and Company - A phase 2, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in adult participants with malignant disease
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.